Redsiweride generic sisave India approved for a total treatment cost of up to $195!

Guide: India's Drug Administration has accelerated approval of two Redsiwe genericdrugs developed by Cipla and Hetero to treat hospitalized adults and children with suspected or laboratory-confirmed COVID-19, severe disease symptoms-grown-in-the-
in May, Gilead's antiviral drug remdesivir was approved by Japan's Ministry of Health, Labour (MHLW) to become the world's first approved drug for the treatment of COVID-19In addition, the drug has been granted emergency use authorization or expansion of the same period in many countries and regions around the world, including the United States, the United Kingdom, the European UnionJune 21, BusinessToday reported that The Drug Administration of India (DCGI) had accelerated approval of two Redsivir generics developed by two local pharmaceutical companies, Cipla and Hetero, to treat adults and children with severe symptoms of the disease, suspected or laboratory-confirmed COVID-19Based on preliminary results from a placebo-controlled phase III clinical trial OF COVID-19 in 1063 patients in more than 60 clinical centers in the United States, Europe and Asia, Redsewe reduced the clinical recovery time of patients by 31% and also showed a reduction in mortality (7.1% vs 11.9%) compared to placeboSipra and Heidlon are both 100mg small bottled injections and must be administered intravenously by a healthcare practitioner at the hospitalSipra's product, called Cipremi, is priced at 3,000-4,000 rupees ($39-52) per doseMrHedlund's product, called Covifor, is priced at Rs 5,000-6,000 ($65-$78) per doseRedsiwe Chemical Structure (photo: chemsrc.com)India's current new crown outbreak is very serious, with 21,000 new cases added in the latest single day, a cumulative total of 426,000 confirmed cases and 137,000 deathsBoth Sipra and MrHedron said they would immediately offer their respective Redsewe generics to patients across IndiaBoth sides have prepared sufficient stocks to meet the needs of the current outbreakUnder current guidelines from the Indian government, a case of COVID-19 patients may need to take 5-6 doses of the drug, which means the total cost of the entire course of antiviral therapy in Redsivir will be as low as $195The Redsewere generics of Sipra and Heidlon were developed under a licensing agreement with Gilead In mid-May, Gilead signed a non-exclusive voluntary licensing agreement with five generic drugmakers in India and Pakistan to supply Ridsiwe to 127 countries around the world, covering almost all low- and middle-income countries May 21 this year, Beximco, a Bangladeshi pharmaceutical company, announced the launch of the world's first Redsivi generic drug Bemsivi, and has offered free treatment to critical LYVID-19 inpatients in government hospitals It should be noted that Beximco is not on the list of five companies that Gilead has signed Beximco has previously claimed that under the World Trade Organization's exemption period for pharmaceutical patents in least developed countries, it can produce generic scantilys versions of branded pharmaceutical products , Redsewe has not yet approved a u.S listing But what is certain is that if it goes on the market, the price of the product will be much higher than in India According to a report released last month by THE DRUG COST WATCHDOG ICER, REDSEWERE'S $4,500 PER COURSE IS CONSIDERED COST-EFFECTIVE Source: Remdesivir OK'd inIndia at $39-52 perdose .